Join the club for FREE to access the whole archive and other member benefits.

Aqtual's blood test could help doctors choose the right treatment for you

01-Nov-2023

Key points from article :

Aqtual, a Hayward, California-based precision medicine company, secures £16 million funding "cell-free DNA platform."

Aqtual's innovative platform analyses cell-free DNA fragments to delve into protein regulation, epigenetics, and transcriptomics.

Company's CEO, highlights the platform's ability to amplify clinically relevant information in cell-free DNA, advancing disease understanding and diagnostic development.

The platform explores previously unexplored cell-free DNA fragments, with potential applications in various clinical areas, including rheumatoid arthritis.

Aqtual initiates a clinical trial for rheumatoid arthritis, aiming to predict the most effective drug classes for individual patients, potentially reducing costly drug trials.

Company's "cell-free DNA platform" can detect unexplored cell-free DNA fragments

Mentioned in this article:

Click on resource name for more details.

Aqtual

Advancing precision medicine products

Aqtual's blood test could help doctors choose the right treatment for you